Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous Immunotherapy in Renal Cell Carcinoma
NCT07872553Phase 4Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab, pembrolizumab in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07872553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872553.